These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16375261)

  • 1. De-immunization of therapeutic proteins by T-cell epitope modification.
    De Groot AS; Knopp PM; Martin W
    Dev Biol (Basel); 2005; 122():171-94. PubMed ID: 16375261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of available design space for identification of non-immunogenic protein therapeutics.
    Lee SC
    Biomed Microdevices; 2010 Apr; 12(2):283-6. PubMed ID: 20012559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.
    Koren E; De Groot AS; Jawa V; Beck KD; Boone T; Rivera D; Li L; Mytych D; Koscec M; Weeraratne D; Swanson S; Martin W
    Clin Immunol; 2007 Jul; 124(1):26-32. PubMed ID: 17490912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of immunogenicity for therapeutic proteins: state of the art.
    De Groot AS; Moise L
    Curr Opin Drug Discov Devel; 2007 May; 10(3):332-40. PubMed ID: 17554860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping.
    De Groot AS; Rayner J; Martin W
    Dev Biol (Basel); 2003; 112():71-80. PubMed ID: 12762506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
    Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis.
    Iwanami K; Matsumoto I; Tanaka Y; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T
    Arthritis Res Ther; 2008; 10(6):R130. PubMed ID: 18992137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics and immunologic investigation on B and T cell epitopes of Cur l 3, a major allergen of Curvularia lunata.
    Sharma V; Singh BP; Gaur SN; Pasha S; Arora N
    J Proteome Res; 2009 Jun; 8(6):2650-5. PubMed ID: 19290623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG
    Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumventing immunogenicity in the development of therapeutic antibodies.
    Holgate RG; Baker MP
    IDrugs; 2009 Apr; 12(4):233-7. PubMed ID: 19350467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteins accessible to immune surveillance show significant T-cell epitope depletion: Implications for vaccine design.
    Halling-Brown M; Shaban R; Frampton D; Sansom CE; Davies M; Flower D; Duffield M; Titball RW; Brusic V; Moss DS
    Mol Immunol; 2009 Aug; 46(13):2699-705. PubMed ID: 19560824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and removal of immunogenicity in therapeutic proteins.
    Baker MP; Jones TD
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):219-27. PubMed ID: 17436557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients.
    Mancini-Bourgine M; Bayard F; Soussan P; Deng Q; Lone YC; Kremsdorf D; Michel ML
    J Virol; 2007 May; 81(10):4963-72. PubMed ID: 17360751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.
    Barbosa MD; Celis E
    Drug Discov Today; 2007 Aug; 12(15-16):674-81. PubMed ID: 17706550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity.
    Tang Y; Lin Z; Ni B; Wei J; Han J; Wang H; Wu Y
    Cancer Immunol Immunother; 2007 Mar; 56(3):319-29. PubMed ID: 16906394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Gag peptide encompassing B- and T-cell epitopes of the caprine arthritis encephalitis virus functions as modular carrier peptide.
    Niederhäuser S; Zahno ML; Nenci C; Vogt HR; Zanoni R; Peterhans E; Bertoni G
    J Immunol Methods; 2009 Mar; 342(1-2):82-90. PubMed ID: 19118559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.